1ST bags deal to consolidate market share
Published 10-AUG-2016 14:26 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
1st Available (ASX:1ST) has continued its quest to become the one online health service provider to rule them all – closing in on a deal which adds 130,000 users to the deck.
In a note to its shareholders today it said that it would move to acquire OzDocsOnline (ODO) for $150,000.
In exchange, 1ST will acquire an online booking service which is used by 130,000 patients and 8000 doctors.
OzDocsOnline is an online booking service which makes revenue by offering patients online access to their own doctor’s services including: online prescription requests; online access to pathology results; online consultations; and online referrals.
The doctors charge patients a flat fee to use each service.
In the 2016 financial year OzDocsOnline took in $310,000 in revenue, with $63,000 of that retained by the company while the rest was distributed to the doctors.
For 1ST, the deal is the latest of a string of deals completed in the last year including the acquisitions of DocAppointments, Clinic Connect, and GObookings.
1ST is attempting to build a hub to connect doctors and patients through a dedicated online portal and suite of apps, consolidating what is currently a fragmented market.
1ST managing director Klaus Bartosch said the deal made sense for both parties.
“Smaller players such as OzDocsOnline struggle to invest in their platforms to provide a future for their customers,” he said. “Not only does this acquisition provide a great future product roadmap for OzDocsOnline customers, but also new opportunities to help grow and manage their businesses.”
“It also helps expand our GP market share, growing our revenue base, consumer base and providing valuable IP (intellectual property).”
The deal is still subject to due diligence so it is not absolutely guaranteed at this stage – investors should seek professional financial advice before deciding whether or not to invest.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
